secwatch.observer — SEC 8-K summary
======================================

Issuer:     HilleVax, Inc. (—)
CIK:        0001888012
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0000950170-24-056949
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HilleVax Q1 net loss widens to $46.8M; cash at $272.7M; NEST-IN1 data due mid-2024
--------------------------------------------------------------------------------

- Net loss $46.8M vs $26.9M YoY; R&D expenses $26.0M (up from $23.2M); G&A $8.5M (up from $5.8M).
- Cash, equivalents and marketable securities $272.7M as of March 31, 2024, down from $303.5M at Dec 31, 2023.
- Topline safety and efficacy data from NEST-IN1 Phase 2b trial of HIL-214 in infants expected in mid-2024.
- Appointed Sean McLoughlin as COO during Q1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1888012/000095017024056949/0000950170-24-056949-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1888012/000095017024056949/hlvx-20240509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-056949

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer